Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, W

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	177 Pages	Coherent Market Insights	May, 2022	CMI17212551

Best Price Guarantee
Price	from $4,500
Length	177 Pages
Publisher	Coherent Market Insights
Published Date	May, 2022
SKU	CMI17212551

Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Anti-Cathespin B antibodies are majorly used for treatment of disease conditions such cancer, traumatic brain injury, Ebola infection, fertility problems, and are currently under research for treatment of SARS-CoV-2. Cathepsins play an important role in protein degradation and processing. Aberrant cathepsin B or L is closely associated with many diseases such as cancer, osteoporosis and autoimmune disorders. Therefore, development of potent and selective cathepsin B and L inhibitors has generated much attention in recent years. Although, several classes of cathepsin inhibitors are presently available, there are still some problems to solve such as a broad-spectrum inhibition to protease, especially cysteine proteases, which lead to unpredictable side effects in clinical trials.
Anti-Cathepsin B antibodies are available from several suppliers. In humans, this protein is encoded by the gene CTSB. The protein may also be known as APPS, CPSB, RECEUP, APP secretase, and amyloid precursor protein secretase. These anti-Cathepsin B antibodies are used for ELISA, western blotting, flow cytometry and other screening purposes.
Market Dynamics
The increasing research and development of anti-cathepsin B antibodies is expected to contribute to the anti-cathespin B market growth over the forecast period. For instance, according to the Springer Nature Journal’s report of July 2017, the effect of cathepsin B inhibitor, E-64, on developmental competency and cryo-survival of pre-implantation ovine IVF derived embryos was assessed. During the test, 1.0 μM of E-64 (Cathepsin B inhibitor) was added during day 3 to 8 of development of blastocyst in IVF derived embryos. And the results showed that the supplementation of IVC media with 1 μM E-64, an exogenous inhibitor of Cathepsins, improves quality and quantity of blastocyst formation. And hence, support the in vitro ovine embryos survival.
Furthermore, there are many developments in research of anti-cathepsin B antibodies. Many researchers are working on finding a cure with the help of anti-cathepsin B antibodies for diseases such as Alzheimer’s disease, rheumatism arthritis, tumor invasion and metastasis, inflammatory airway disease, chronic obstructive pulmonary disease, osteoarthritis, pneumocystis carinii, acute pancreatitis, and bone and joint disorders.
Key features of the study:
This report provides in-depth analysis of the global anti-cathespin B market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global anti-cathespin B market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global anti-cathespin B market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-cathespin B market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Anti-Cathespin B Market, By Type:
Primary Antibodies
Proteins and Peptides
Lysates
Global Anti-Cathespin B Market, By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
Global Anti-Cathespin B Market, By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
Global Anti-Cathespin B Market, By End User:
Pharmaceutical Companies
Academic and Research Institutes
Global Anti-Cathespin B Market, By Region:
North America
By Country:
U.S.
Canada
By Type:
Primary Antibodies
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Type:
Primary Antibodies
Screening Kits
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Type:
Primary Antibodies
Screening Kits
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Type:
Primary Antibodies
Screening Kits
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Type:
Primary Antibodies
Screening Kits
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Type:
Primary Antibodies
Screening Kits
Proteins and Peptides
Lysates
By Research Application:
Cancer
Traumatic Brain Injury
Ebola Infection
Fertility Treatment
Others
By Technique:
Immunohistochemistry
Immunofluorescence
Western Blotting
ELISA
Flow Cytometry
Others
By End User:
Pharmaceutical Companies
Academic and Research Institutes
Company Profiles
Merck KGaA*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bio-Techne
BioVision Inc.
Santa Cruz Biotechnology, Inc.
MedChemExpress
BioCat GmbH
ApexBio Technology
Cayman Chemical
Selleck Chemicals
BOC Sciences
AG Scientific
Virobay Inc.
Abcam Plc
“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Overview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Product Type; Market Snippet, By Research Area; Market Snippet, By Application; Market Snippet, By End User; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Market Trends; Regulatory Scenario; Reimbursement Scenario; New Product Launches/Approvals; Mergers & Acquisitions; Porter’s Analysis; PEST Analysis
4. Global Anti-Cathepsin B Market, COVID-19 Impact Analysis: Pre-COVID-19 Market Scenario; Post COVID-19 Market Scenario; Strategies
5. Global Anti-Cathepsin B Market, By Product Type, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Primary Antibodies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Proteins and Peptides; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Lysates; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Anti-Cathepsin B Market, By Research Area, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Traumatic Brain Injury; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Ebola Infection; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Fertility Treatment; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
7. Global Anti-Cathepsin B Market, By Application, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Immunohistochemistry; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Immunofluorescence; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Western Blotting; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); ELISA; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Flow Cytometry; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
8. Global Anti-Cathepsin B Market, By End User, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Pharmaceutical Companies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Academic and Research Institutes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
9. Global Anti-Cathepsin B Market, By Region, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, By Region, 2022 and 2028 (%); Y-o-Y Growth Analysis, By Region, 2017 - 2028; Regional Trends; North America; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); U.S.; Canada; Europe; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); China; Japan; India; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Africa; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million); North Africa; Central Africa; South Africa; Middle East; Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Research Area, 2017 - 2028, (US$ Million); Market Size and Forecast, By Application, 2017 - 2028, (US$ Million); Market Size and Forecast, By End User, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); GCC Countries; Israel; Rest of Middle East
10. Competitive Landscape: Company Profiles; Merck KGaA; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Bio-Techne; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; BioVision Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Santa Cruz Biotechnology, Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; MedChemExpress; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; BioCat GmbH; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; ApexBio Technology; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Cayman Chemical; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Selleck Chemicals; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; BOC Sciences; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; AG Scientific; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Virobay Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Abcam Plc; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies
11. Section: References; Research Methodology; About us and Sales Contact; *Browse 43 market data tables and 39 figures on "Global Anti-Cathepsin B Market” - forecast to 2028”